Hepatitis A virus (HAV) infection can cause illness with fever, malaise, nausea, abdominal pain, and jaundice. Although infection in young children is typically asymptomatic, older children and adults generally develop symptoms that can last for several months [1] . The efficacy of inactivated hepatitis A vaccines has been demonstrated in controlled trials, and vaccines were licensed in the United States in 1995-1996. Implementation of routine childhood hepatitis A vaccination has resulted in dramatic reductions in the incidence of disease [1] . The duration of protection afforded by childhood vaccination remains unknown.
Historically, the rates of hepatitis A among Alaska Native people were substantially higher than the overall US rate, primarily fueled by a pattern of recurrent large epidemics occurring every 7-10 years [2, 3] . These periodic outbreaks of hepatitis A in Alaska Native communities led to early investigation of vaccine-based control strategies in Alaska [4] . We previously reported the results of a randomized trial to assess the immunogenicity of an inactivated hepatitis A vaccine administered according to 3 vaccination schedules in Alaska Native children and 1 schedule in Alaska Native and non-Alaska Native adults [5] . We now report the results of testing for anti-body to HAV (anti-HAV) up to 10 years after completion of the primary vaccination series.
PARTICIPANTS, MATERIALS, AND METHODS
We conducted a prospective long-term follow-up study among a cohort of adults and children who had received 3 doses of inactivated hepatitis A vaccine. This study was approved by the institutional review boards of the Alaska Area Native Health Service, Indian Health Service, and Centers for Disease Control and Prevention. This study was also approved by 2 Alaska Native health organizations: the Alaska Native Tribal Health Consortium and the Southcentral Foundation. Adult participants and the parents of pediatric participants provided informed consent; children provided written informed assent. After the first 5 years of follow-up, participants were asked to consent (adults) or assent (children) to a 5-year extension of the follow-up study.
Participants and procedures. The study was conducted during 1991-2004. Participants included Alaska Native children aged 3-6 years at the time of enrollment and Alaska Native and nonNative adults. All participants were seronegative for anti-HAV prior to receipt of 3 doses of inactivated hepatitis A vaccine (Havrix; GlaxoSmithKline Biologicals). Children were randomized to receive 3 doses of 360 ELISA units (EU) of vaccine according to 1 of 3 schedules: additional doses at 1 and 2 months after the first vaccination (hereafter, "0-1-2 months"), additional doses at 1 and 6 months after the first vaccination ("0-1-6 months"), or additional doses at 1 and 12 months after the first vaccination ("0-1-12 months"). Adults received 720 EU of vaccine, at 0-1-12 months. Only adults employed by the participating hospital were asked to consent to the study extension after 5 years. All children were invited to participate in the study extension.
Serum specimens were obtained for anti-HAV testing approximately 1 month and 1, 2, 3, 4, 5, 8, 9, and 10 years after receipt of the third dose of vaccine. We have previously reported the peak antibody response measured ϳ1 month after completion of the primary series [5] . All specimens were stored and then tested at the end of the 10-year follow-up period. Serum samples collected 1 month after completion of the primary series were retested with the other follow-up specimens to facilitate accurate comparison. Anti-HAV testing was done by ELISA (DiaSorin); results were quantitative and expressed in milli-international units (mIU). Anti-HAV levels 20 mIU/mL, the lower limit of detection of the assay, were considered indicative of seroprotection.
At each follow-up visit, participants were asked about their history of jaundice or symptoms of illness compatible with hepatitis. Serum levels of alanine aminotransferase (ALT) were also measured at each visit. Persons with ALT levels Ͼ60 units/L underwent further laboratory testing for evidence of infection with HAV, hepatitis B virus (HBV), or hepatitis C virus (HCV) and were referred to a physician for evaluation. In addition to the blood work and physical examination, record reviews were conducted to look for other possible causes of the ALT elevation, such as concurrent illness, diabetes, medication, or obesity.
Data analysis. Anti-HAV concentrations were log-transformed prior to calculating the geometric mean concentration (GMC). Comparisons of GMC between the 3 groups of children receiving vaccine on different schedules were made by using an analysis of variance. Comparisons of GMC between adults and children who were vaccinated on the 0-1-12 month schedule were made using an independent t test. Comparisons of GMC within groups over time were made with a paired t test by use of the logtransformed values. Long-term estimates of antibody persistence were made on the basis of published methods by using a log-linear model of decline in GMC of antibody from its peak through 10 years of follow-up [6] . Reported estimated persistence of anti-HAV gives the time at which the GMC would be expected to decrease to 20 mIU/mL. This estimate was based on the rate of decline observed during the study period. Participants who received a booster dose of hepatitis A vaccine were excluded from analysis from the time of the fourth dose. Proportions were compared by use of the 2 test or Fisher's exact test, as appropriate. All P values were 2-sided.
RESULTS
A total of 144 children and 128 adults were enrolled (table 1) . The mean number of follow-up specimens collected per participant was 5 (range, 1-10). The peak GMC of antibody (which occurred Ͻ3 months after completion of the primary vaccine series) was highest in children vaccinated on the 0-1-12 schedule (7785 mIU/mL [95% confidence interval {CI}, 6056 -10,009 NOTE. Vaccination schedules: 0-1-2, additional doses of vaccine at 1 and 2 months after the first vaccination; 0-1-6, additional doses of vaccine at 1 and 6 months after the first vaccination; 0-1-12, additional doses of vaccine at 1 and 12 months after the first vaccination. mIU/mL]), followed by those vaccinated on the 0-1-6 schedule (5486 mIU/mL [95% CI, 3771-7983 mIU/mL]); children vaccinated on the 0-1-2 schedule had the lowest peak GMC (1012 mIU/mL [95% CI, 680 -1507 mIU/mL]) (table 2). The peak GMC in adults was 5825 mIU/mL (95% CI, 4736 -7165 mIU/ mL); this did not statistically significantly differ from the GMC in children vaccinated according to the same schedule.
Follow-up testing among children revealed significant differences in GMC among recipients of the 3 different vaccine schedules, with higher GMC observed in children vaccinated according to the 0-1-12 month schedule (table 2). These differences in GMC persisted throughout the study period, but were no longer statistically significant 5 years after completion of the vaccination primary series. There was a significant correlation between peak anti-HAV concentration and follow-up anti-HAV levels for all groups of children (r ϭ 0.67 at 1 year after the third dose and r ϭ 0.69 at 10 years after the third dose; P Ͻ .001 for both). The rate of decline in anti-HAV concentration did not differ significantly between the 3 groups after adjustment for peak antibody level (data not shown). Anti-HAV concentrations were not significantly different by the age or sex of the participating child.
Similar to the result observed among children, there was a significant correlation between peak anti-HAV concentration and the subsequent follow-up results in adults (r ϭ 0.80 at 1 year after the third dose and r ϭ 0.80 at 10 years after the third dose; P Ͻ .001 for both). Among adults, increasing age was significantly associated with lower antibody concentrations (P Ͻ .05) through 5 years of follow-up (table 3) . Lower anti-HAV concentrations were measured in men, compared with Table 2 . Geometric mean concentration (GMC) of antibody to hepatitis A virus among participants in Alaska for 10 years after completing the primary vaccination series, according to vaccination schedule. NOTE. Data are GMC in mIU/mL (95% confidence interval). Vaccination schedules: 0-1-2, additional doses of vaccine at 1 and 2 months after the first vaccination; 0-1-6, additional doses of vaccine at 1 and 6 months after the first vaccination; 0-1-12, additional doses of vaccine at 1 and 12 months after the first vaccination. those measured in women; this difference was significant at 6 months, 4 years, and 5 years, but not at later follow-up time periods. After adjustment for peak anti-HAV level, decline in antibody concentration did not differ significantly by age or sex. Among participants vaccinated according to the 0-1-12 month schedule, children had significantly higher anti-HAV levels, compared with adults, at 2, 3, 4, and 8 -9 years (table 2) . Differences between anti-HAV concentrations in adults and children were no longer significant after adjustment for peak anti-HAV level.
The percentage of participants demonstrating an anti-HAV level 20 mIU/mL at each of the follow-up periods is shown in table 4. Of 67 children who participated in 10-year follow-up, all retained and anti-HAV level 20 mIU/mL. Anti-HAV levels remained 20 mIU/mL in 25 (96%) of 26 adults who participated in follow-up testing at 8 -9 years and in all 7 adults who had a 10-year follow-up specimen available. We assessed the differences between participants who underwent follow-up testing at 10 years and those who did not. The duration of follow-up did not differ significantly by age, sex, race, or the magnitude of the peak anti-HAV concentration after completing the primary vaccination series.
During the study there were only 5 specimens (from 3 people) in which the anti-HAV level was Ͻ20 mIU/mL. One of these individuals was an adult whose last 3 specimens (at 4, 5, and 9 years) all had an anti-HAV level Ͻ20 mIU/mL. Two children who were vaccinated on the 0-1-2 schedule also lost detectable levels of antibody: one at 1 year after vaccination and the other at 9 years after vaccination.
After an initial rapid decline in anti-HAV level immediately following vaccination, the slope of the decline decreased ( figure  1 ). Based on a log-linear model of rates of decline, the duration of antibody persistence was estimated to be at least 21 years for adults. The estimated duration of antibody persistence in children varied depending on the schedule used for primary vaccination: 27 years for the 0-1-2 months schedule, 22 years for the 0-1-6 months schedule, and 27 years for the 0-1-12 months schedule.
Among study participants, 30 adults and 9 children had 1 samples with elevated ALT levels (60 units/L) over the course of their follow-up. Upon record review, reasons for the elevated ALT level were found for 28 persons (72%), including elevated body mass index with probable nonalcoholic fatty liver disease (n ϭ 22 [56%]), HCV infection (n ϭ 2 [5%]), alcohol abuse (n ϭ 2 [5%]), renal failure (n ϭ 1 [3%]), and HBV and HCV coinfection (n ϭ 1 [3%]). An elevated ALT level of unknown etiology was documented in 11 participants. Serum specimens were available for 9 of these 11 participants, and all tested negative for anti-HAV IgM at the time of the elevated ALT level. All 11 persons had ALT levels within the normal range at the follow-up testing performed 6-12 months after the elevated ALT level was detected.
DISCUSSION
The available inactivated hepatitis A vaccine formulations are highly immunogenic. Previously published serologic studies suggest that immunity after hepatitis A vaccination is maintained for up to 6 years in children and up to 12 years in adults [6 -10] . We report new information about the persistence of anti-HAV in children and adults up to 10 years after completion of the primary vaccination series. We found that nearly all children and adults retained anti-HAV at levels considered protective for at least 10 years after administration of inactivated hep- (100) 22 (100) 7 (100) NOTE. Data are no. of subjects with anti-HAV level 20 mIU/mL (% of persons tested at that time interval). Vaccination schedules: 0-1-2, additional doses of vaccine at 1 and 2 months after the first vaccination; 0-1-6, additional doses of vaccine at 1 and 6 months after the first vaccination; 0-1-12, additional doses of vaccine at 1 and 12 months after the first vaccination.
a One participant had an anti-HAV level of 50 mIU/mL on original testing, but when stored serum samples were retested for this analysis, the anti-HAV level was Ͻ20 mIU/mL. atitis A vaccine. When children were compared with adults, children had higher peak anti-HAV levels after vaccination and maintained higher antibody levels throughout the years of follow-up.
Populations in which routine childhood vaccination has been introduced have experienced dramatic reductions in disease incidence [1, [11] [12] [13] . In 1996, the US Advisory Committee on Immunization Practices (ACIP) recommended that persons in groups at high risk for hepatitis A and children living in communities with high rates of disease should receive hepatitis A vaccine [14] . High rates of hepatitis A with widespread periodic outbreaks led to early implementation of universal vaccination of children living in Alaska Native and American Indian communities. The state of Alaska has offered hepatitis A vaccination to all children aged 2-18 years, regardless of ethnicity, since 1996, resulting in significant reductions in disease [15] . In 1999, the ACIP recommendation was expanded to include targeted vaccination of children living in states with high rates of hepatitis A [15] . Compared with the average rate during 1990 -1997, the 2003 overall rate of hepatitis A in the United States declined 76%, and the rate in states with recommended vaccination programs declined by 88% [13] . The ACIP again expanded the hepatitis A vaccine recommendations in 2006 to include vaccination of all US children at age 12-23 months [1] . As rates of disease continue to fall and the risk of HAV exposure decreases, breakthrough infections will become an even less sensitive indicator of waning immunity, and studies that measure the persistence of anti-HAV will be even more essential.
Although children in this study received 3 doses of hepatitis A vaccine at 360 EU units per dose (the formulation available at the time) rather than the currently licensed schedule of 2 doses at 720 EU per dose, the peak GMCs of antibody achieved by these 2 regimens appear to be comparable. Bell et al. reported peak GMCs of 3166 mIU/mL and 3153 mIU/mL among children receiving 720 EU of hepatitis A vaccine at ages 12 and 18 months and ages 15 and 21 months, respectively [16] . Wang et al. reported that among children between the ages of 5 and 8 years who were vaccinated with Vaqta (Merck) on a 2-dose regimen (at 0 and 6 months), the GMC was 7585 mIU/mL [17] . Comparable immunogenicity has also been documented for 2-dose combined hepatitis A/B vaccine (720 EU inactivated hepatitis A vaccine at 0 and 6 months) and 3-dose hepatitis A/B vaccine (360 EU inactivated hepatitis A vaccine, 0-1-6 months) [18, 19] . Given the similar immunogenicity profiles of these regimens, the duration of antibody persistence among persons vaccinated with the currently licensed dose and schedule is likely to be similar to that of the study participants described herein.
Estimates of long-term antibody persistence can be made by using a variety of mathematical models. On the basis of findings in this study, we projected that children would retain protective levels of anti-HAV for 22 years after vaccination on a 0-1-6 months schedule or for 27 years after vaccination on a 0-1-12 schedule. Other estimates of the persistence of anti-HAV have been published previously. Chan et al. suggested that children who were vaccinated at ages 4 -15 years with 360 EU of inactivated hepatitis A vaccine on a 0-1-6 month schedule could retain protective antibody levels for 14 years [7] . Using a log-linear regression model, Fan et al. projected that more than half of children who were vaccinated at ages 1-7 years with 360 EU of inactivated hepatitis A vaccine on a 0-1-6 month schedule would remain seropositive for 20 years [8] . Similarly, Maiwald et al. modeled persistence of seroprotection at Ͼ15 years in adults vaccinated with 720 EU of inactivated hepatitis A vaccine on a 0-1-6 month schedule [9] . On the basis of findings from a 6-year follow-up study among adults vaccinated with inactivated hepatitis A vaccine, Van Herck and Van Damme estimated the duration of seroprotection to be at least 20 -25 years [6] . Because the rate of decline in anti-HAV concentration decreases over time, these extrapolations (which are based on a log-linear decline) may underestimate the true duration of antibody persistence. Further, the anti-HAV concentration needed to confer protection against hepatitis A is unknown; the 20 mIU/mL cut point used in this analysis was the lower limit of detection of the assay. It is possible that protection against infection is achieved with lower, or even undetectable, antibody levels. Additionally, inactivated hepatitis A vaccine is known to induce cellular immunity, and an immunologic memory response may provide protection beyond the duration of detectable antibody [10, 20, 21] . Therefore, the duration of protection may actually be substantially longer than suggested by these model-based estimates of decline in antibody level.
There are several limitations to this study. The GMC of antibody for children vaccinated on the 0-1-2 month schedule actually increased somewhat at ϳ2 years of age; the reasons for this are unclear. In the region where the study was conducted, during the time period that the increase was noted, the incidence of hepatitis A was ϳ6.5 cases/100,000 population, and only 4 cases of hepatitis A were reported among Alaska Native children Ͻ10 years of age (personal communication, L. Castrodale). Both the low incidence of disease circulating in the community at the time and the relatively small rise in GMC make exposure to infection unlikely. It is possible that the increase in GMC resulted from administration of an additional dose of hepatitis A vaccine that was not ascertained during the review of medical records. If boosting of anti-HAV levels did occur in a subset of participants, our analysis could overestimate the persistence of antibody. In total, there were 17 participants whose anti-HAV concentration increased at some point during the study. Removal of these 17 individuals from the model of antibody persistence yielded comparable estimates of persistence (20 -25 years in the model that did not include these individuals vs. 21-27 years in the model that included all participants). This was a long-term study, and some participants were lost to follow-up as the study progressed. In the later years of the study, the declining sample size may have affected our ability to detect statistically significant differences between participants on different vaccine schedules. The majority of participants in this study were of Alaska Native heritage. There is no evidence to suggest differences in vaccine immunogenicity in this population and vaccination programs among Alaska Native people have yielded reductions in disease comparable to those seen in non-Alaska Native people.
The recent recommendation for routine hepatitis A vaccination of children 12-23 months old will likely result in further decline in the rate of hepatitis A in the United States. The findings of this study document that seroprotective anti-HAV levels are retained for at least 10 years after vaccination. Hepatitis A booster doses after completion of the primary vaccination series do not appear to be warranted and are not currently recommended [22] . Antibody concentrations do decline over time and ongoing monitoring is needed to evaluate immunity beyond 10 years after vaccination to assess whether persons vaccinated as children will be protected throughout adulthood. Studies are also needed to assess the long-term immunogenicity of the currently recommended 2-dose regimen and to evaluate the immunologic memory response to antigen exposure, particularly in persons who no longer have protective concentrations of anti-HAV.
